Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics plus bismuth-containing quadruple therapy in refractory Helicobacter pylori infection
ChiCTR2600123681Phase 4Not yet recruiting
- Sponsor
- Ningxia Hui Autonomous Region People's Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of Medilac-S, vonoprazan, colloidal bismuth pectin, minocycline and amoxicillin in Refractory Helicobacter pylori infection (2 arms), sponsored by Ningxia Hui Autonomous Region People's Hospital. Primary endpoints: Helicobacter pylori eradication rate and Adverse events. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Medilac-Svonoprazancolloidal bismuth pectinminocyclineamoxicillin
03
Conditions
Refractory Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2600123681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123681.